CN103997894B - 乳癌的治疗 - Google Patents

乳癌的治疗 Download PDF

Info

Publication number
CN103997894B
CN103997894B CN201280048192.2A CN201280048192A CN103997894B CN 103997894 B CN103997894 B CN 103997894B CN 201280048192 A CN201280048192 A CN 201280048192A CN 103997894 B CN103997894 B CN 103997894B
Authority
CN
China
Prior art keywords
substituted
alkyl
compound
formula
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280048192.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN103997894A (zh
Inventor
A·A·普罗特
J·瑞彻
D·克齐兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maddie Wilson Prostate Treatment Co Ltd
University of Colorado Boulder
Original Assignee
University of Colorado Boulder
Medivation Prostate Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103997894(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Colorado Boulder, Medivation Prostate Therapeutics LLC filed Critical University of Colorado Boulder
Publication of CN103997894A publication Critical patent/CN103997894A/zh
Application granted granted Critical
Publication of CN103997894B publication Critical patent/CN103997894B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280048192.2A 2011-07-29 2012-07-27 乳癌的治疗 Active CN103997894B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161513361P 2011-07-29 2011-07-29
US61/513,361 2011-07-29
PCT/US2012/048471 WO2013066440A1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Publications (2)

Publication Number Publication Date
CN103997894A CN103997894A (zh) 2014-08-20
CN103997894B true CN103997894B (zh) 2016-08-24

Family

ID=48192564

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280048192.2A Active CN103997894B (zh) 2011-07-29 2012-07-27 乳癌的治疗

Country Status (18)

Country Link
US (4) US9517229B2 (cg-RX-API-DMAC7.html)
EP (4) EP2739153B1 (cg-RX-API-DMAC7.html)
JP (2) JP6158180B2 (cg-RX-API-DMAC7.html)
KR (1) KR101923250B1 (cg-RX-API-DMAC7.html)
CN (1) CN103997894B (cg-RX-API-DMAC7.html)
BR (1) BR112014002200A2 (cg-RX-API-DMAC7.html)
CA (1) CA2843417C (cg-RX-API-DMAC7.html)
CY (1) CY1121038T1 (cg-RX-API-DMAC7.html)
DK (1) DK2739153T3 (cg-RX-API-DMAC7.html)
EA (1) EA028452B1 (cg-RX-API-DMAC7.html)
ES (1) ES2696074T3 (cg-RX-API-DMAC7.html)
HU (1) HUE040524T2 (cg-RX-API-DMAC7.html)
MX (1) MX359664B (cg-RX-API-DMAC7.html)
PH (1) PH12014500248B1 (cg-RX-API-DMAC7.html)
PL (1) PL2739153T3 (cg-RX-API-DMAC7.html)
PT (1) PT2739153T (cg-RX-API-DMAC7.html)
SI (1) SI2739153T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013066440A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2739153B1 (en) * 2011-07-29 2018-08-22 Medivation Prostate Therapeutics LLC Treatment of breast cancer
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
LT3305285T (lt) 2012-09-26 2020-12-10 Aragon Pharmaceuticals, Inc. Anti-androgenai, skirti gydyti nametastazavusį kastracijai atsparų prostatos vėžį
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US9937169B2 (en) * 2013-04-17 2018-04-10 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
AU2013404949B2 (en) * 2013-11-07 2018-10-18 Deciphera Pharmaceuticals, Llc Methods for inhibiting TIE2 kinase useful in the treatment of cancer
JP6945587B2 (ja) * 2013-11-07 2021-10-06 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
EP3148336B1 (en) 2014-05-28 2019-10-02 Eisai R&D Management Co., Ltd. Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
MX2017007707A (es) 2014-12-12 2018-03-06 Medivation Prostate Therapeutics Llc Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama.
WO2016141167A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Combination liposomal pharmaceutical formulations
US10736845B2 (en) 2015-03-03 2020-08-11 Cureport Inc. Dual loaded liposomal pharmaceutical formulations
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
KR102795129B1 (ko) 2017-06-22 2025-04-15 셀진 코포레이션 B형 간염 바이러스 감염을 특징으로 하는 간세포 암종의 치료
CA3079135A1 (en) 2017-10-16 2019-04-25 Arturo Molina Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
BR112020015581A2 (pt) 2018-01-31 2021-02-02 Deciphera Pharmaceuticals, Llc terapia de combinação para o tratamento de tumores estromais gastrointestinais
SG11202007287XA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of mastocytosis
WO2020113088A1 (en) * 2018-11-30 2020-06-04 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
CN119950433A (zh) 2019-12-30 2025-05-09 德西费拉制药有限责任公司 非晶型激酶抑制剂制剂及其使用方法
PL4084779T3 (pl) 2019-12-30 2025-02-24 Deciphera Pharmaceuticals, Llc Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
EP4188330A4 (en) * 2020-08-03 2024-09-04 Oncocyte Corporation CLASSIFICATION OF TUMORS AND PREDICTION OF RESPONSE
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101454002A (zh) * 2006-03-27 2009-06-10 加利福尼亚大学董事会 用于治疗前列腺癌和与雄激素受体相关的疾病的雄激素受体调节剂
WO2010099238A1 (en) * 2009-02-24 2010-09-02 Medivation Prostate Therapeutics, Inc. Specific diarylhydantoin and diarylthiohydantoin compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
KR101332924B1 (ko) * 2005-05-13 2013-11-26 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
EP1954708A4 (en) 2005-11-23 2009-05-13 Univ Utah Res Found Methods and compositions involving intrinsic genes
CN102755318B (zh) 2006-03-29 2014-09-10 加利福尼亚大学董事会 二芳基硫代乙内酰脲化合物
PE20121470A1 (es) * 2007-10-26 2012-11-18 Univ California Compuestos de diarilhidantoina como antagonistas del receptor de androgeno
US8450290B2 (en) * 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009114534A1 (en) * 2008-03-14 2009-09-17 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
PL2297359T4 (pl) 2008-05-30 2014-07-31 Univ North Carolina Chapel Hill Profile ekspresji genów do przewidywania skutków raka piersi
EP2416657A4 (en) 2009-04-09 2012-09-05 Medivation Prostate Therapeutics Inc COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
US8507195B2 (en) * 2009-08-20 2013-08-13 The Regents Of The University Of Colorado MiRNAs dysregulated in triple-negative breast cancer
EP2485804A4 (en) 2009-10-07 2015-07-29 Medivation Technologies Inc SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINOAREN COMPOUNDS AND N, N'-BIS-ARYL UREA COMPOUNDS
EP2685988A4 (en) 2011-03-15 2014-08-20 Univ North Carolina Methods of treating breast cancer with anthracycline therapy
EP2739153B1 (en) * 2011-07-29 2018-08-22 Medivation Prostate Therapeutics LLC Treatment of breast cancer
WO2013082440A2 (en) 2011-11-30 2013-06-06 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with taxane therapy
AU2013306380A1 (en) 2012-08-23 2015-03-05 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
US20140154681A1 (en) 2012-11-12 2014-06-05 Nanostring Technologies, Inc. Methods to Predict Breast Cancer Outcome
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
MX2017007707A (es) 2014-12-12 2018-03-06 Medivation Prostate Therapeutics Llc Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101454002A (zh) * 2006-03-27 2009-06-10 加利福尼亚大学董事会 用于治疗前列腺癌和与雄激素受体相关的疾病的雄激素受体调节剂
WO2010099238A1 (en) * 2009-02-24 2010-09-02 Medivation Prostate Therapeutics, Inc. Specific diarylhydantoin and diarylthiohydantoin compounds

Also Published As

Publication number Publication date
PT2739153T (pt) 2018-11-28
EP3430907A1 (en) 2019-01-23
CA2843417C (en) 2018-08-21
PH12014500248B1 (en) 2018-08-31
KR20140107174A (ko) 2014-09-04
CY1121038T1 (el) 2019-12-11
US20140296312A1 (en) 2014-10-02
JP2014524934A (ja) 2014-09-25
PL2739153T3 (pl) 2019-04-30
HUE040524T2 (hu) 2019-03-28
HK1201413A1 (en) 2015-09-04
WO2013066440A1 (en) 2013-05-10
US20170087132A1 (en) 2017-03-30
US9517229B2 (en) 2016-12-13
PH12014500248A1 (en) 2014-03-17
WO2013066440A9 (en) 2013-07-18
JP2017141269A (ja) 2017-08-17
EP3791724A1 (en) 2021-03-17
BR112014002200A2 (pt) 2017-03-07
EP2739153B1 (en) 2018-08-22
JP6158180B2 (ja) 2017-07-05
ES2696074T3 (es) 2019-01-14
MX359664B (es) 2018-10-05
EA028452B1 (ru) 2017-11-30
KR101923250B1 (ko) 2018-11-28
CA2843417A1 (en) 2013-05-10
DK2739153T3 (en) 2018-12-03
EP3610731A1 (en) 2020-02-19
US10111861B2 (en) 2018-10-30
HK1198867A1 (en) 2015-06-19
EA201400178A1 (ru) 2014-11-28
CN103997894A (zh) 2014-08-20
SI2739153T1 (sl) 2018-12-31
EP2739153A4 (en) 2015-03-11
US20210069154A1 (en) 2021-03-11
EP2739153A1 (en) 2014-06-11
MX2014001218A (es) 2014-08-22
US20190262315A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
CN103997894B (zh) 乳癌的治疗
WO2022133731A1 (en) Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor and for the treatment of cancers
JP2020193234A (ja) 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤
JP6433085B2 (ja) がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
JP6440212B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
CN101370497A (zh) 利用parp抑制剂的联合疗法
US9464093B2 (en) Substituted imidazo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines and oxazolo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines for treating brain cancer
WO2013067151A1 (en) Treatment methods using diarylthiohydantoin derivatives
CN105579439B (zh) 辐射减轻性药物制剂
JP2010514734A (ja) 腸障害の治療のためのイソソルビドモノニトレート誘導体
JP2004533992A (ja) フレデリカマイシンＡ化合物を用いたＰｉｎ１関連状態の阻害方法
WO2018125968A1 (en) Glut4 selective inhibitors for cancer therapy
JP2022527451A (ja) Ｐｋｍ２モジュレーターおよびその使用方法
HK1201413B (en) Treatment of breast cancer
JP2023552368A (ja) Ｙボックス結合タンパク質１阻害剤
JP2022532186A (ja) 非晶質のｐｉ３ｋ阻害剤及びこれを含有する医薬組成物
WO2025237421A1 (zh) 作为雄激素受体调节剂的新型偶联分子及其应用
JP2019189625A (ja) がんの治療のためのｐｉｍキナーゼ阻害剤と組み合わせたペプチドエポキシケトンプロテアソーム阻害剤
HK1198867B (en) Treatment of breast cancer
HK1229744B (zh) 2-乙酰基萘并[2，3-b]呋喃-4，9-二酮用於治疗癌症的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1201413

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: American California

Co-patentee after: Colorado University Administrative Affairs Committee (Yi Ge body corporate)

Patentee after: Mehdi Vee Xun prostate therapeutics limited liability company

Address before: American California

Co-patentee before: Colorado University Administrative Affairs Committee (Yi Ge body corporate)

Patentee before: Mai Diweixun prostate treatment limited company

CP01 Change in the name or title of a patent holder
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1201413

Country of ref document: HK

CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: American Colorado

Co-patentee after: Colorado University Administrative Affairs Committee (Yi Ge body corporate)

Patentee after: Maddie Wilson prostate treatment Co., Ltd.

Address before: American California

Co-patentee before: Colorado University Administrative Affairs Committee (Yi Ge body corporate)

Patentee before: Mehdi Vee Xun prostate therapeutics limited liability company

CP02 Change in the address of a patent holder

Address after: New York State, USA

Patentee after: Maddie Wilson prostate treatment Co.,Ltd.

Patentee after: THE REGENTS OF THE University OF COLORADO

Address before: Colorado, USA

Patentee before: Maddie Wilson prostate treatment Co.,Ltd.

Patentee before: THE REGENTS OF THE University OF COLORADO

CP02 Change in the address of a patent holder